Cumulative Inflammatory Phagocytic Reprocessing of Persistent Particulate Aluminum

Abstract

A phagocyte that engulfs a persistent particulate load does not neutralise it: the cell may be activated, injured or replaced, but the material itself survives, and what happens next depends on which cell takes it up in its place. This hypothesis paper proposes a multiexposure–multicompartment convergence architecture: distinct infections, injuries and other inflammatory stimuli could repeatedly affect several tissue compartments — for example skin, enthesis, synovium or neurovascular niches — while separate exposures to particulate formulations contribute cargos of distinct fate and phagocytic handling. Repeated inflammatory episodes can alter the retention, turnover, transfer and local re-phagocytosis of a pre-existing particulate load, a process termed cumulative inflammatory phagocytic reprocessing, which could act as a shared amplifier across compartments. This amplification is not uniform: depending on its inflammatory signature, a given contextual modifier — a concurrent infection, for instance — can potentiate or suppress different components of the pathway, so that direction, not only magnitude, is itself part of what the model predicts. It integrates established observations of aluminum-adjuvant uptake by phagocytes, formulation-dependent innate activation, local persistence, and, in mice, low-magnitude CCL2-dependent particle translocation from muscle to brain. The resulting architecture links cumulative exposure, myeloid trafficking, tissue receptivity, intercurrent inflammation and host susceptibility as determinants of whether a contained load becomes locally immunologically relevant, such that several compartments could cross their local thresholds at different times and manifest as distinct or coexisting autoimmune phenotypes. Because the relevant exposure would be an individual trajectory rather than a single dose followed by a short-latency event, the model further predicts that any true signal would be diluted within passive pharmacovigilance systems built around temporal proximity. The framework is explicitly scoped to this shared amplification layer, not to the antigenic and tissue-specific determinants that govern the identity of each disease. It generates experimental and epidemiological predictions through which the model can be refined or disproved.